Company intelligence / Profile preview

Sigolis

Cambridge, Massachusetts, United States

Ownership: Private
Employees: ~96
Development stage: Other

Overview

Developing cell therapy programs using SLTx platform; lead program SIG-002 for type 1 diabetes planned IND-enabling studies in 2023 with IND submission expected in 2024; acquired by Eli Lilly in August 2023.

Therapeutic areas: HematologyImmunologyEndocrinologyRare DiseasesGastroenterology
Modalities: Cell therapy
Industry: Biotech

Partnerships

Eli Lilly

Beyond the preview

Go deeper on Sigolis.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sigolis.

Explore the full profile